These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 21039311)
21. Effect of Baseline Characteristics on the Pain Response to Pregabalin in Fibromyalgia Patients with Comorbid Depression. Silverman SL; Backonja M; Pauer L; Landen J; Bhadra Brown P; Scavone JM; Vissing R; Clair A Pain Med; 2018 Mar; 19(3):419-428. PubMed ID: 28525632 [TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety of Pregabalin in Patients with Fibromyalgia and Comorbid Depression Taking Concurrent Antidepressant Medication: A Randomized, Placebo-controlled Study. Arnold LM; Sarzi-Puttini P; Arsenault P; Khan T; Bhadra Brown P; Clair A; Scavone JM; Driscoll J; Landen J; Pauer L J Rheumatol; 2015 Jul; 42(7):1237-44. PubMed ID: 26034150 [TBL] [Abstract][Full Text] [Related]
23. Pain responder analysis: use of area under the curve to enhance interpretation of clinical trial results. Cappelleri JC; Bushmakin AG; Zlateva G; Sadosky A Pain Pract; 2009; 9(5):348-53. PubMed ID: 19549060 [TBL] [Abstract][Full Text] [Related]
24. [Questionable documentation of the effect of pregabalin in fibromyalgia]. Holtedahl R Tidsskr Nor Laegeforen; 2010 May; 130(10):1032-6. PubMed ID: 20489805 [TBL] [Abstract][Full Text] [Related]
25. Clinical characteristics, pharmacotherapy and healthcare resource use among patients with fibromyalgia newly prescribed gabapentin or pregabalin. Gore M; Sadosky AB; Zlateva G; Clauw DJ Pain Pract; 2009; 9(5):363-74. PubMed ID: 19500273 [TBL] [Abstract][Full Text] [Related]
26. Estimating the economic benefits of positive shifts in fibromyalgia severity: an exploratory analysis based on modeling of clinical trial data of pregabalin. Cappelleri JC; Bushmakin AG; Zlateva G; Chandran A J Med Econ; 2013; 16(1):55-61. PubMed ID: 22954060 [TBL] [Abstract][Full Text] [Related]
27. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arnold LM; Goldenberg DL; Stanford SB; Lalonde JK; Sandhu HS; Keck PE; Welge JA; Bishop F; Stanford KE; Hess EV; Hudson JI Arthritis Rheum; 2007 Apr; 56(4):1336-44. PubMed ID: 17393438 [TBL] [Abstract][Full Text] [Related]
28. Time to improvement of pain and sleep quality in clinical trials of pregabalin for the treatment of fibromyalgia. Arnold LM; Emir B; Pauer L; Resnick M; Clair A Pain Med; 2015 Jan; 16(1):176-85. PubMed ID: 25529830 [TBL] [Abstract][Full Text] [Related]
30. The safety and efficacy of pregabalin for treating subjects with fibromyalgia and moderate or severe baseline widespread pain. Clair A; Emir B Curr Med Res Opin; 2016; 32(3):601-9. PubMed ID: 26694975 [TBL] [Abstract][Full Text] [Related]
31. The effect of anxiety and depression on improvements in pain in a randomized, controlled trial of pregabalin for treatment of fibromyalgia. Arnold LM; Crofford LJ; Martin SA; Young JP; Sharma U Pain Med; 2007; 8(8):633-8. PubMed ID: 18028041 [TBL] [Abstract][Full Text] [Related]
32. Medication dosing patterns associated with duloxetine and pregabalin among patients with fibromyalgia. Sun P; Zhao Y; Zhao Z; Watson P Curr Med Res Opin; 2011 Sep; 27(9):1793-801. PubMed ID: 21810060 [TBL] [Abstract][Full Text] [Related]
33. Comparisons of the efficacy and safety of duloxetine for the treatment of fibromyalgia in patients with versus without major depressive disorder. Arnold LM; Hudson JI; Wang F; Wohlreich MM; Prakash A; Kajdasz DK; Chappell AS Clin J Pain; 2009; 25(6):461-8. PubMed ID: 19542792 [TBL] [Abstract][Full Text] [Related]
34. Time to onset of neuropathic pain reduction: A retrospective analysis of data from nine controlled trials of pregabalin for painful diabetic peripheral neuropathy and postherpetic neuralgia. Sharma U; Griesing T; Emir B; Young JP Am J Ther; 2010; 17(6):577-85. PubMed ID: 20393345 [TBL] [Abstract][Full Text] [Related]
35. Pregabalin augmentation of quetiapine therapy in the treatment of fibromyalgia: an open-label, prospective trial. Calandre EP; Morillas-Arques P; Rodriguez-Lopez CM; Rico-Villademoros F; Hidalgo J Pharmacopsychiatry; 2007 Mar; 40(2):68-71. PubMed ID: 17447176 [TBL] [Abstract][Full Text] [Related]
36. Clinical characteristics, pharmacotherapy, and healthcare resource use among patients with fibromyalgia newly prescribed pregabalin or tricyclic antidepressants. Gore M; Tai KS; Chandran A; Zlateva G; Leslie D J Med Econ; 2012; 15(1):32-44. PubMed ID: 21970698 [TBL] [Abstract][Full Text] [Related]
37. Comparison of medication adherence and healthcare costs between duloxetine and pregabalin initiators among patients with fibromyalgia. Zhao Y; Sun P; Watson P; Mitchell B; Swindle R Pain Pract; 2011; 11(3):204-16. PubMed ID: 20807351 [TBL] [Abstract][Full Text] [Related]
38. Initial use of pregabalin, patterns of pain-related pharmacotherapy, and healthcare resource use among older patients with fibromyalgia. Gore M; Sadosky A; Zlateva G; Clauw D Am J Manag Care; 2010 May; 16(5 Suppl):S144-53. PubMed ID: 20586523 [TBL] [Abstract][Full Text] [Related]
39. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arnold LM; Lu Y; Crofford LJ; Wohlreich M; Detke MJ; Iyengar S; Goldstein DJ Arthritis Rheum; 2004 Sep; 50(9):2974-84. PubMed ID: 15457467 [TBL] [Abstract][Full Text] [Related]
40. Potential drug-drug and drug-condition interactions among fibromyalgia patients initiating pregabalin or duloxetine: prevalence and health care expenditure impact. Johnston SS; Udall M; Cappelleri JC; Johnson BH; Shrady G; Chu BC; Silverman SL Pain Med; 2014 Aug; 15(8):1282-93. PubMed ID: 24401017 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]